Peptides are the molecules your body already uses to heal, grow, and thrive. We broke down 12 of the most researched ones so you actually understand what the science is saying.
Before you can appreciate what peptides do, you need to know what they are.
Peptides are short chains of amino acids — the same building blocks as protein, just smaller, faster, and far more targeted. Your body is already running on thousands of them right now.
Insulin? A peptide. The hormones regulating your hunger, your sleep, your immune response, your skin repair? All peptides. They're not exotic — they're the operating system your biology has always used.
What makes synthetic peptide research so exciting is the idea of precision. Unlike a blunt-force drug, a well-designed peptide can theoretically walk up to one specific receptor in one specific tissue and do exactly one job. That's the promise researchers are chasing.
Tap any card to go deep — mechanisms, research, and what the science actually says.
Every peptide follows the same basic playbook. Here's what happens from the moment one enters your body.
Some peptides your body makes naturally. Others are synthetic analogs — lab-engineered to mirror what nature already built, but more stable and longer-lasting.
Like a key made for one specific lock, each peptide binds to a receptor designed to receive it — and only it. That specificity is what separates peptides from most conventional drugs.
Binding flips a switch inside the cell. Signaling cascades fire, genes get turned on or off, and the cell gets its marching orders — all from one small molecule making contact.
Tissue heals faster. Hormones release. Fat gets mobilized. Inflammation dials down. The response depends entirely on which peptide docked where — and that's exactly the point.
Semaglutide and Tirzepatide are everywhere right now. Here's the actual science of how they work — step by step.
Peptide research doesn't live in one lane. Here's where the science is focused right now.
Type, research focus, and where each one stands in the approval pipeline right now.
| Peptide | Type | Primary Focus | Status |
|---|---|---|---|
| BPC-157 | Peptide fragment | Wound healing, GI protection, tendon repair | Preclinical |
| TB-500 | Thymosin β-4 fragment | Muscle repair, angiogenesis, inflammation | Preclinical |
| Epitalon | Tetrapeptide | Telomere elongation, aging, sleep | Research |
| MOTS-c | Mitochondrial peptide | Insulin sensitivity, metabolic regulation, aging | Research |
| GHK-Cu | Copper-binding tripeptide | Collagen synthesis, wound healing, antioxidant | Topical Use |
| CJC-1295 | GHRH analog | Growth hormone release, body composition | Research |
| Ipamorelin | GHS / Ghrelin mimetic | Selective GH secretion, body composition | Research |
| AOD-9604 | HGH fragment 176-191 | Fat metabolism, lipolysis, anti-obesity | Phase IIb |
| Tesamorelin | GHRH analog | Visceral fat reduction, HIV lipodystrophy | FDA Approved* |
| Retatrutide | GLP-1/GIP/Glucagon agonist | Obesity, metabolic syndrome, glucose | Phase III |
| Tirzepatide | GLP-1/GIP dual agonist | Type 2 diabetes, obesity management | FDA Approved |
| Semaglutide | GLP-1 receptor agonist | Diabetes, weight management, CV risk | FDA Approved |
* Tesamorelin approved for HIV-associated lipodystrophy only. All research-stage peptides lack general clinical approval.